Trending Up0.0200 (1.1111%)
  • Bid / Lots
    1.8000/ 2
  • Ask / Lots
    1.8300/ 3
  • Open / Previous Close
    1.8000 / 1.8000
  • Day Range
    Low 1.7600
    High 1.8252
  • 52 Week Range
    Low 1.2400
    High 5.3225
  • Volume

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 1.8
09:32 ET37151.81
09:34 ET40281.8
09:38 ET7341.8
09:41 ET1001.8
09:48 ET8741.8
09:54 ET2861.825
09:56 ET24491.79
09:57 ET101001.795
09:59 ET2361.775
10:01 ET2401.775
10:03 ET1101.7836
10:06 ET2511.7895
10:08 ET1001.775
10:10 ET2401.77
10:14 ET1001.76
10:15 ET19451.78
10:17 ET2001.77
10:26 ET1001.79
10:28 ET10001.7888
10:30 ET9321.78
10:33 ET1001.76
10:35 ET50001.7699
10:39 ET11001.79
10:42 ET1001.77
10:46 ET8201.79
10:51 ET35081.8
10:57 ET1001.785
11:00 ET1001.785
11:06 ET2861.7999
11:09 ET62961.8
11:18 ET5561.8252
11:24 ET7001.81
11:29 ET20521.8
11:36 ET3001.8
11:44 ET5461.79
11:49 ET1001.79
11:54 ET8001.8
12:02 ET1001.8
12:14 ET1001.8
12:16 ET2001.8
12:34 ET2001.8
12:38 ET18001.8
12:39 ET1001.8
12:41 ET70481.8
12:52 ET18571.81
01:03 ET2001.81
01:06 ET4001.82
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesVAXX
Vaxxinity Inc
United StatesBIVI
BioVie Inc
United StatesORIC
Oric Pharmaceuticals Inc
United StatesQSI
Quantum-Si Inc
United StatesNKTX
Nkarta Inc
United StatesCELC
Celcuity Inc
As of 2023-05-30

Company Information

Vaxxinity, Inc. is a biotechnology company. The Company is engaged in the development of rationally designed prophylactic and therapeutic vaccines to combat chronic disorders and infectious diseases with large patient populations and unmet medical needs. The Company’s synthetic peptide vaccine platform (Vaxxine Platform) has enabled the innovation of pipeline candidates designed to bring the efficiency of vaccines to the treatment of chronic diseases, including Alzheimers, Parkinsons, migraine, and hypercholesterolemia. Its pipeline consists of six programs, which include UB-311, UB-312, VXX-301, UB-313, VXX-401 and UB-612. Its UB-311 targets toxic forms of aggregated amyloid-b (Ab) in the brain to fight AD. Its UB-312 targets toxic forms of aggregated a-synuclein in the brain to fight PD and other synucleinopathies, such as Lewy body dementia (LBD) and multiple system atrophy (MSA). Its UB-313 targets Calcitonin Gene-Related Peptide (CGRP) to fight migraines.

Contact Information

1717 Main Street, Suite 3388DALLAS, TX, United States 75201


Executive Chairman
Louis Reese
President, Chief Executive Officer, Co-Founder, Director
Mei Mei Hu
Senior Vice President - Finance and Accounting
Jason Pesile
Chief Scientific Officer
Farshad Guirakhoo
General Counsel, Company Secretary
Rene Paula

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.